Response: Conflicting data on the prognostic significance of FLT3-TKD mutations in cytogenetically normal acute myeloid leukemia (CN-AML) might be related to many factors, including techniques used to detect FLT3-TKD, differences in patient populations studied, and treatment regimens

We appreciate the comments of Mead et al regarding our recent article,[1][1] and agree it is important to discern the reason(s) for the apparent differences in outcomes of patients with cytogenetically normal acute myeloid leukemia (CN-AML) and point mutations in the FLT3 -tyrosine kinase domain (